APREPITANT 80 EUROLAB Capsules, hard 80 mg

Nchi: Tanzania

Lugha: Kiingereza

Chanzo: Tanzania Medicinces & Medical Devices Authority

Viambatanisho vya kazi:

Aprepitant

Inapatikana kutoka:

Eurolab (Pty) Ltd, SOUTH AFRICA

ATC kanuni:

aprepitant

INN (Jina la Kimataifa):

Aprepitant

Kipimo:

80 mg

Dawa fomu:

Capsules, hard

Viwandani na:

Rontis Hellas S.A., Medical and Pharmaceutical Products, GREECE

Bidhaa muhtasari:

Physical description: Opaque, size 2 hard gelatine capsule with a white body and cap, containing white to off-white pellets; Local technical representative: BB PHARMA CONSULTANCY LTD (3955)

Idhini hali ya:

Registered/Compliant

Idhini ya tarehe:

2021-08-20

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Repimend 80 mg hard capsules
Repimend 125 mg hard capsules
Repimend 125 mg + 80 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Repimend_ 80 mg hard capsules _
Each hard capsule contains 80 mg of aprepitant.
Excipient with known effect
Each capsule contains 80 mg of sucrose (in the 80 mg capsule).
Repimend
_ 125 mg hard capsules _
Each hard capsule contains 125 mg of aprepitant.
Excipient with known effect
Each capsule contains 125 mg of sucrose (in the 125 mg capsule).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
_Repimend80 mg hard capsules _
Opaque hard gelatin capsules with a white body and cap, containing
white to off-white pellets.
_Repimend125 mg hard capsules _
Opaque hard gelatin capsules with a white body and pink cap,
containing white to off-white pellets.
4.
CLINICAL PARTICULARS
1. THERAPEUTIC INDICATIONS
Prevention nausea and vomiting associated with highly and moderately
emetogenic cancer
chemotherapy in adults and adolescents from the age of 12.
Repimend125 mg/80 mg is given as part of combination therapy (see
section 4.2).
2. POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults _
Repimendis given for 3 days as part of a regimen that includes a
corticosteroid and a 5-HT
3
antagonist. The recommended dose is Repimend125 mg orally once daily
one hour before
start of chemotherapy on Day 1 and Repimend80 mg orally once daily on
Days 2 and 3 in the
morning.
The following regimens are recommended in adults for the prevention of
nausea and vomiting
associated with emetogenic cancer chemotherapy:
_ Highly Emetogenic Chemotherapy Regimen _
_ _
DEXAMETHASONE should be administered 30 minutes prior to chemotherapy
treatment on Day
1 and in the morning on Days 2 to 4. The dose of dexamethasone
accounts for active
substance interactions.
Day 1
Day 2
Day 3
Day 4
Aprepitant
125 mg
orally
80 mg
orally
80 mg
orally
none
Dexamethaso
ne
12 mg
orally
8 mg
orally
8 mg
orally
8 mg
orally
5-HT
3
an